Rescue of cognitive deficits in APP/PS1 mice by accelerating the aggregation of ß-amyloid peptide

 

Zhang, J., Lai, Y., Mi, P., et al.

Alzheimer's Research and Therapy 2019, vol:11, 106 doi: 10.1186/s13195-019-0560-6

Abstract

Brain amyloid deposition is one of the main pathological characteristics of Alzheimer’s disease (AD). Soluble oligomers formed during the process that causes β-amyloid (Aβ) to aggregate into plaques are considered to have major neurotoxicity. Currently, drug development for the treatment of Alzheimer’s disease has encountered serious difficulties. Our newly proposed solution is to accelerate the aggregation of Aβ to reduce the amount of cytotoxic Aβ oligomers in brain tissue. This strategy differs from the existing strategy of reducing the total Aβ content and the number of amyloid plaques.

View Publication

Topics: Neurodegenerative diseases, Monolith – MicroScale Thermophoresis, MST,  Publications

 

 

Previous Article
New peptide inhibitors modulate the self-assembly of islet amyloid polypeptide residues 11–20 in vitro
New peptide inhibitors modulate the self-assembly of islet amyloid polypeptide residues 11–20 in vitro

Up next
An engineered monomer binding-protein for alpha-syn efficiently inhibits the proliferation of amyloid fibrils
An engineered monomer binding-protein for alpha-syn efficiently inhibits the proliferation of amyloid fibrils

Characterize the molecular mechanisms of neurodegenerative diseases

Learn how